Emerson unveils new PAT tools to speed drug development and improve production

803-pat

Emerson is working with Broadley-James to beta test mammalian cell growth models that help maximize PAT benefits.
High resolution image








MEDIA CONTACT:

Grace Capwell
Emerson Automation Solutions
+1 (512) 834-7214
Grace.Capwell@emerson.com


Cell growth model and process analytics accelerate product creation, rapid manufacturing scale-up and early real-time release of biological products

Austin, Texas (March 27, 2008) -- Emerson Process Management has expanded its software library with new PAT tools designed to speed development and improve production of life-saving drugs. Emerson's new high fidelity cell growth models and its multivariate process analytics accelerate product development, speed scale-up to full production, and enable real-time release of manufactured biological products. 

Emerson's most recent work is the development models for mammalian cell processes that are currently in Beta testing.  Cell growth models for bacterial, fungal, and yeast fermentations are available now.  Previous studies indicate that the models can be used to prototype model predictive control of growth and product formulation rates which can in some cases reduce batch times by 40% and improve yields by 10%.

Biopharmaceutical product development is difficult and risky.  Currently more than 200 biotechnology medicines are in development for more than 100 diseases.  Due to process complexity, the products generally result only after lengthy iteration between process development and commercialization. Traditional development requires hundreds of trial batches, and then extensive data collection for final selection of processing conditions.  Emerson's new PAT tools shorten the time and cost of development, and use real-time data to improve quality and yield of released final product.

The new tools use off-line dynamic computer simulations of bioprocesses that can be run at up to 1000X real time to determine optimum settings for real-time production.  Also, for on-line operation, embedded analytics tools may be used to detect faults and predict end of batch values of quality parameters continuously in real time, helping to optimize batch process control and enable the efficiency of real-time release. 

Emerson's new PAT tools for bioreactor modeling are in a library of software modules that run in its DeltaV™ digital automation system.  The model, configuration, and tools are used to create a "virtual plant" that can simulate batch execution faster than by physical experimentation.  PAT tools are also being developed as embedded software in the DeltaV system to support on-line analytics.  The DeltaV system is commonly used in product development and is the process management system embedded in the Broadley-James bioreactor family. 

The bioreactor models are available as a complete DeltaV solution designed specifically for the customer's product development application. Engineering and configuration services and training are included, supporting user needs for efficient operation and maintenance of the production simulation software.

Additional resources:
• Join the Emerson Exchange 365 Community
• Connect with Emerson Automation Solutions via
   Twitter Facebook LinkedIn Google+ YouTube


About Emerson
Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. Our Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Emerson Commercial and Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency, and create sustainable infrastructure. For more information visit Emerson.com.

Please enable JavaScript to use this website.